PAULA SITU: Open Payments
NPI 1598703241 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,370 in 11 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $257 · 2025 $1,370
Food & beverage: $1,370
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $238 |
| Edwards Lifesciences Corporation | 1 | $197 |
| Dexcom, Inc. | 1 | $169 |
| Madrigal Pharmaceuticals | 1 | $145 |
| Alnylam Pharmaceuticals Inc. | 1 | $144 |
| Insulet Corporation | 2 | $144 |
| Novo Nordisk Inc | 1 | $124 |
| GENZYME CORPORATION | 1 | $111 |
| Novartis Pharmaceuticals Corporation | 1 | $98 |
Products named: SAPIEN 3 Ultra RESILIA, Dexcom G6 Transmitter, REZDIFFRA, ONPATTRO, Omnipod, UZEDY, Ozempic, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
